LifeCord Overview
LifeCord develops a Transfemoral Mitral Chordal Repair system, addressing the significant challenge of mitral regurgitation.
Cumulative Funding Raised Over Time ($)
$1.3MApr 2024
Latest News
growth-positive
LifeCord's mitral chordal repair solution offers an alternative to open-heart surgery | CTech
LifeCord, a company specializing in innovative mitral chordal repair solutions, has raised $1.3 million in a seed investment round. The funding will be used to advance their minimally invasive transcatheter system for treating degenerative mitral regurgitation (DMR), a condition affecting a significant portion of the population. LifeCords device offers a safer alternative to open-heart surgery, preserving the mitral leaflet and allowing for future interventions. The company is backed by a strong intellectual property portfolio and strategic partnerships with MEDX Xelerator, a multinational medical device corporation, and a U.S. healthcare institution. The funds will support the completion of First-in-Human trials and further R&D efforts, positioning LifeCord as a key player in the $2 billion mitral valve intervention market.
InvestmentPartners
| Sector | Health Tech & Life Sciences |
Funding
| Total funding | $1.3M |
| Last funding | $1.3M |
| Stage | Seed |
| Rounds | 1 |
| Investors | 1 |
Team Members
2
Employees: 1-10
Web & Social Links
| Website | www.life-cord.com/ |
Locations
Ariel Sharon Blvd 8, Or Yehuda, Israel
Photos & Videos
No files yet
LifeCord Business
Business models
B2C
Product stage
R&D
Employees
1-10
Sector
Health Tech & Life SciencesMedical DevicesMedical Treatment & TherapeuticsTarget Customer
Healthcare & Life SciencesHealthcareProvidersCore Technology
—Tags (5)
healthcarecardiologyheart-diseasessurgery-toolssurgeryLifeCord Financials
$1.3M
Total funding
Undisclosed
Capital raised
$1.3M
Last funding
Seed
Funding stage
1
Total rounds
1
Investors
Cumulative Funding Raised Over Time ($)
$1.3MApr 2024
Private Equity Funding
Seed
Apr 2024
$1.3M
MEDX Xelerator
LifeCord Lifecycle
Cumulative Funding Raised Over Time
$1.3MApr 2024
All Events
Seed
Apr 2024
$1.3M
MEDX Xelerator
LifeCord News
1 article
growth-positive
LifeCord's mitral chordal repair solution offers an alternative to open-heart surgery | CTech
LifeCord, a company specializing in innovative mitral chordal repair solutions, has raised $1.3 million in a seed investment round. The funding will be used to advance their minimally invasive transcatheter system for treating degenerative mitral regurgitation (DMR), a condition affecting a significant portion of the population. LifeCords device offers a safer alternative to open-heart surgery, preserving the mitral leaflet and allowing for future interventions. The company is backed by a strong intellectual property portfolio and strategic partnerships with MEDX Xelerator, a multinational medical device corporation, and a U.S. healthcare institution. The funds will support the completion of First-in-Human trials and further R&D efforts, positioning LifeCord as a key player in the $2 billion mitral valve intervention market.
InvestmentPartners
Employee Info
| Employees (range) | 1-10 |
| Exact count | 5 |
| Team members | 2 |
Similar Companies
Similar companies data is computed dynamically and not stored in the entity profile. This section requires implementing a similarity query (e.g. by classification overlap, sector, district).
This entity has 6 classification IDs that could be used for matching.
LifeCord Internal
Recent Updates
No update log entries.
Note: Free-text notes visible in the original Finder "Internal" tab are not present in the imported profile data. Only the update audit log is available.
Admin Info
| Confidence | 72/100 |
| Missing | sector, description, video or image, markets, not claimed |
| BI Verification | Matan Eblagon |
| Registrar ID | 516871548 |
| Creator | Ortal Wein |
| Creator email | ortalw@sncentral.org |
| Last updater | Matan Eblagon |
| Updater email | matane@sncentral.org |
| Last update | 2024-12-01T00:00:00.000Z |
| Created | 2024-11-27T00:00:00.000Z |